Efficacy and safety of rivaroxaban on anti -deep venous thrombosis for patients undergoing hip arthroplasty
10.13699/j.cnki.1001-6821.2015.12.009
- VernacularTitle:髋关节置换术后利伐沙班预防下肢深静脉血栓的疗效与安全性
- Author:
Jian ZHOU
1
;
Zhong-Da LIU
;
Wei-Long LIN
Author Information
1. 丽水市中医院骨伤科
- Keywords:
rivaroxaban;
hip arthroplasty;
deep venous thrombosis;
low molecular heparin;
safety
- From:
The Chinese Journal of Clinical Pharmacology
2015;(12):1106-1108
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the efficacy and safety of rivaroxaban on anti -deep venous thrombosis for patients with hip arthroplasty. Methods A total of 63 cases who scheduled for hip arthroplasty were recruited and were randomly divided into treatment group ( n=31 ) and control group ( n =32 ) .Patients in treatment group were administered with rivaroxaban 10 mg? d-1 6 h after surgery orally qd for 35 days, and patients in the control group were injected with low molecular heparin 4100 U 12 h after surgery for 14 days.The data of blood loss, blood transfusion rate and deep venous thrombosis risk were compared between the two groups.Results There were 30 patients finishing the treatment of 3 months follow -up in treatment group with the incidence of deep venous thrombosis being 13.3%.There were 31 cases finishing the 3 months follow-up in the control group with the incidence of deep venous thrombosis being 16.2%.There was no statistical difference between the two groups (P>0.05).The platelet and coagulation function change of the two groups were not statistically different before and after the treatment ( P>0.05 ) .The blood loss was ( 1320.6 ±202.4 ) mL and (1301.1 ±232.6) mL in treatment group and control group respectively with no statistical difference ( P>0.05 ) .Conclusion Rivaroxaban can significantly decrease the risk of deep vein thrombosis in patients undergoing hip arthroplasty without increasing the risk of bleeding, similar to the efficacy of low molecular heparin.
